Healthcare stocks were mixed in late with the NYSE Healthcare
Sector Index rising about 0.1% and shares of healthcare companies
in the S&P 500 slipping about 0.1% as a group.
In company news, Supernus Pharmaceuticals Inc. (
) is now up around 13% at near $8.40, but is off a new 52 week high
of $9.05 hit earlier after the drug-maker last night confirmed U.S.
regulators have approved treprostinil extended-release tablets to
treat pulmonary arterial hypertension in patients seeking to
improve their ability to exercise.
SUPN developed the extended-release formulation of the drug -
which will be marketed commercially as Orenitram - under a license
agreement with United Therapeutics Corp (
). The product also uses SUPN's osmotic technology platform and
calls on UTHR to pay milestone fees and royalties as the drug
achieves certain sales marks in the United States and other
UTHR shares are now down 1.5% as the stock gives in to moderate
profit-taking after rising to a new, all-time high-water mark
In other sector news,
(+) IMUC, (+11.5%) First patient receives the company's ICT-121
cancer vaccine in Phase I testing of the prospective brain cancer
treatement in patients with recurrent glioblastoma.
(-) UTHR, (-1.5%) Jefferies Group boosts its price target for
the drug-maker by $15 to $91 a share.
Copyright (C) 2014 MTNewswires.com. All rights reserved. Unauthorized reproduction is strictly prohibited.